These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 23622837)

  • 1. [Prevention of bacterial risk: pathogen inactivation/detection of bacteria].
    Morel P; Naegelen C; Deschaseaux M; Bardiaux L
    Transfus Clin Biol; 2013 May; 20(2):109-14. PubMed ID: 23622837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Control of the bacterial risk of transfusion in France in 2013].
    Morel P; Deschaseaux M; Bertrand X; Naegelen C; Leconte des Floris MF; Bardiaux L
    Transfus Clin Biol; 2013 May; 20(2):174-81. PubMed ID: 23622838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Towards bacterial detection in labile blood products].
    Morel P
    Transfus Clin Biol; 2005 Jun; 12(2):215-20. PubMed ID: 15894499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bacterial detection leading to pathogen inactivation].
    Morel P; Deschaseaux M; Naegelen C; Bardiaux L; des Floris MF; Pouthier F
    Transfus Clin Biol; 2005 Jun; 12(2):142-9. PubMed ID: 15894506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Photochemical inactivation of pathogens in platelets and plasma: five years of clinical use in routine and hemovigilance. Towards a change of paradigm in transfusion safety].
    Cazenave JP
    Transfus Clin Biol; 2011 Apr; 18(2):53-61. PubMed ID: 21474358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of reasons for not implementing pathogen inactivation for platelet concentrates.
    Lozano M; Cid J
    Transfus Clin Biol; 2013 May; 20(2):158-64. PubMed ID: 23587612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacterial contamination of platelet components: potential solutions to prevent transfusion-related sepsis.
    Corash L
    Expert Rev Hematol; 2011 Oct; 4(5):509-25. PubMed ID: 21939419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Residual risk and retrospective analysis of transfusion-transmitted bacterial infection reported by the French National Hemovigilance Network from 2000 to 2008.
    Lafeuillade B; Eb F; Ounnoughene N; Petermann R; Daurat G; Huyghe G; Vo Mai MP; Caldani C; Rebibo D; Weinbreck P
    Transfusion; 2015 Mar; 55(3):636-46. PubMed ID: 25257344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemovigilance monitoring of platelet septic reactions with effective bacterial protection systems.
    Benjamin RJ; Braschler T; Weingand T; Corash LM
    Transfusion; 2017 Dec; 57(12):2946-2957. PubMed ID: 28840603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of platelet concentrates and plasma with riboflavin and UV light: Impact in bacterial reduction.
    Bello-López JM; Delgado-Balbuena L; Rojas-Huidobro D; Rojo-Medina J
    Transfus Clin Biol; 2018 Sep; 25(3):197-203. PubMed ID: 29656962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transfusion-transmitted bacterial infection: risks, sources and interventions.
    Wagner SJ
    Vox Sang; 2004 Apr; 86(3):157-63. PubMed ID: 15078249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacterial contamination of platelets.
    Palavecino EL; Yomtovian RA; Jacobs MR
    Transfus Apher Sci; 2010 Feb; 42(1):71-82. PubMed ID: 19939734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative values of the interventions of diversion and improved donor-arm disinfection to reduce the bacterial risk from blood transfusion.
    McDonald CP; Roy A; Mahajan P; Smith R; Charlett A; Barbara JA
    Vox Sang; 2004 Apr; 86(3):178-82. PubMed ID: 15078252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of pathogen inactivation on cryoprecipitate: a functional and quantitative evaluation.
    Kamyszek RW; Foster MW; Evans BA; Stoner K; Poisson J; Srinivasan AJ; Thompson JW; Moseley MA; Mooberry MJ; Welsby IJ
    Blood Transfus; 2020 Nov; 18(6):454-464. PubMed ID: 33000752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Universal implementation of pathogen inactivation in labile blood products is a major step towards transfusion safety].
    Cazenave JP
    Bull Acad Natl Med; 2010 Dec; 194(9):1707-19; discussion 1719-20. PubMed ID: 22043595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacterial contamination and proliferation during the storage of cellular blood products.
    Blajchman MA
    Vox Sang; 1998; 74 Suppl 2():155-9. PubMed ID: 9704439
    [No Abstract]   [Full Text] [Related]  

  • 17. Improving the bacteriological safety of platelet transfusions.
    Blajchman MA; Goldman M; Baeza F
    Transfus Med Rev; 2004 Jan; 18(1):11-24. PubMed ID: 14689374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the effectiveness of a pathogen inactivation technology against clinically relevant transfusion-transmitted bacterial strains.
    Schmidt M; Hourfar MK; Sireis W; Pfeiffer U; Göttig S; Kempf VA; McDonald CP; Seifried E
    Transfusion; 2015 Sep; 55(9):2104-12. PubMed ID: 26013691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transfusion-transmitted bacterial infection.
    Krishnan LA; Brecher ME
    Hematol Oncol Clin North Am; 1995 Feb; 9(1):167-85. PubMed ID: 7737940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogen inactivation: coming of age.
    Lozano M; Cid J
    Curr Opin Hematol; 2013 Nov; 20(6):540-5. PubMed ID: 24104416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.